Trade RNAZ stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
TransCode Therapeutics, Inc. (RNAZ) is trading at US$1.76, up 6.67% today as of Sep 21, 16:00 EDT. The company has a market capitalisation of US$3.04M. Over the past 52 weeks, RNAZ has traded between US$1.58 and US$20.99. On Syfe you can trade RNAZ with $0 commission and add it to your watchlist.
| Previous close | US$1.65 |
|---|---|
| Market cap | US$3.04M |
| 52-week range | US$1.58 – US$20.99 |
| Volume | 65.41K |
| Exchange | US |
Add to Watchlist
Set Price Alert
TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. Its lead product candidate is TTX-MC138, an antisense inhibitor of an oncogenic microRNA. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.
Year: 2021
TransCode Says Phase 1a Cancer Trial Meets Safety Goal, Advances Drug to Phase 2a
Jun 3, 1:04 PM · MT Newswires
TransCode Registers 1.53 Million Shares for YA II PN Resale Under Equity Purchase Deal
May 1, 2:43 PM · MT Newswires
TransCode Therapeutics, Inc. (RNAZ) stock is trading at US$1.76, +6.67% from the previous close of US$1.65.
The market cap for TransCode Therapeutics, Inc. (RNAZ) stock is approximately US$3.04M.
The 52-week high for TransCode Therapeutics, Inc. (RNAZ) stock is US$20.99.
The 52-week low for TransCode Therapeutics, Inc. (RNAZ) stock is US$1.58.
TransCode Therapeutics, Inc. (RNAZ) does not currently pay a dividend.
Stay on top of RNAZ
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
